ADMA Biologics IPO Research Information

ADMA Biologics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on ADMA Biologics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
ADMA Biologics	ADMA - NASDAQ	$8.50-$9.50	$8.50	$7.00	3.35 million	10/17/2013
Underwriter(s): Oppenheimer & Co., BMO Capital Markets
Co-Manager(s): Ladenburg Thalmann, Maxim Group, Laidlaw & Co.(UK)
Industry: Health Care
Filing(s): Filed 2013-02-11

ADMA Biologics Quote & Chart - Click for current quote - ADMA

About ADMA Biologics (adapted from ADMA Biologics prospectus):
They are a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases.

This description is adapted from ADMA Biologics prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as ADMA Biologics "ADMA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.